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els, discrete-event-simulation models to equation-based models. Individual char-
acteristics relevant for PM include individual risk factors, clinical properties, pa-
tient history, severity of disease, number of repeated events. Different approaches
were used to link risk factors and predictors to prognosis and treatment decisions
and success as well as resource use. E.g., POHEM is a leading Canadian microsimu-
lation for health care policies. Applications range from lung cancer treatment,
breast cancer prevention to the evaluation of cardiovascular diseases. To support
decisions on HIV prevention Rauner et. al. built a discrete-event-simulation where
breast feeding mothers are even linked to their children. Overall microsimulation
has been successfully applied e.g., in cancer research, chronic diseases or screen-
ing and prevention. CONCLUSIONS: Microsimulation techniques are broadly ap-
plied but still underrepresented in economic evaluations for health care policies.
Microsimulation is a powerful tool for evaluating PM-strategies, because it can be
used to incorporate the genetic and clinical heterogeneity of individuals as well as
personalized decision algorithms.
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GENERAL METHODOLOGICAL ISSUES IN COST-EFFECTIVENESS ANALYSIS
INSPIRED BY THE ASSESSMENT OF DASATINIB, NILOTINIB AND IMATINIB FOR
CHRONIC MYELOID LEUKAEMIA
Hoyle MW
University of Exeter, Exeter, UK
OBJECTIVES: In 2009, the cost-effectiveness of drugs for chronic myeloid leukae-
mia for use in the UK NHS was evaluated by the National Institute of Health and
Clinical Excellence (NICE). Two questions were considered: a) dasatinib vs. nilotinib
vs. high-dose imatinib vs. interferon-alpha for imatinib-resistant patients, and b)
dasatinib vs. nilotinib vs. interferon-alpha for imatinib-intolerant patients. Here,
three methodological issues are discussed which strongly influenced the cost-
effectiveness of these drugs. These issues are also important in estimation of the
cost-effectiveness of many other drugs and other health technologies. METHODS:
1) Overall survival: Several methods were considered for estimating overall sur-
vival, including those used by the drug sponsors, Novartis and Bristol-Myers
Squibb; 2) Sources of mortality: Two approaches were considered: a) split by mor-
tality due to chronic myeloid leukaemia and general mortality or b) both combined;
3) Treatment duration: This was reported in none of the trials. Several methods of
estimating treatment duration were considered. RESULTS: 1) Overall survival: It
was not possible to extrapolate overall survival because it was very immature in
the trials. Instead, the preferred method was estimation via a surrogate relation-
ship using major cytogenetic response; 2) Sources of mortality: Option (a) was
preferred; and 3) Treatment duration: the preferred method was by reference to
mean progression-free survival, adjusted for treatment cessation due to adverse
events. CONCLUSIONS: To estimate the cost-effectiveness of health technologies
for a variety of conditions, it is recommended that 1) if overall survival from a trial
is immature, it can be estimated by surrogate relationships; 2) for chronic condi-
tions, the analyst should consider modelling separately disease-specific mortality
and general mortality; and 3) for drugs, the mean number of doses in clinical trials
should be reported so that it is not necessary to estimate this important informa-
tion using indirect methods.
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OBJECTIVES: Objective of the SCAN project is to support pharma companies in
Italy, in managing the complexity of the new drugs pricing process approval at both
National and regional level, by identifying a fair price based on the real new drug
value. The rationale behind SCAN is first to analyze in a structured and evidence
based way all benefits related to a new drug vs a comparator, from clinical to
pharmacoeconomic point of view, and then to get a fair price weighting all benefits
with a National Board of expert who validate the whole process and result.
METHODS: SCAN is an integrated method of data analysis, software platform and
expert opinion, where all the required market access tools are linked: marketing
forecasts, market analysis and budget impacts at both National and Regional level.
Added value of the platform is the value-based pricing that determines the price of
the new drug based on its added value (ie efficacy, safety) compared to the standard
of care for a certain disease, validated by a multidisciplinary National Board of
expert, made of pharmacologists, pharmacoeconomists and clinicians. Some trials
have been done comparing lapatinib (that has recently got the price in the meta-
static breast cancer indication from the National Drug Agency) versus
trastuzumab. RESULTS: The price obtained with the software simulations pro-
duced a value-based ex factory price/pack of 1500€, compared to 1225€ determined
by the Italian National Agency (AIFA). CONCLUSIONS: The performed simulation
shows that the system is a robust tool to determine a value based price which takes
into account the innovativeness of the drug.
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OBJECTIVES: To develop a flexible and generic economic model quantifying poten-
tial savings associated with Rx-to-OTC switches from the perspective of European
policy makers and health care budget holders. METHODS: A systematic review of
the literature of Rx-to-OTC switches was performed to understand the populations
involved, key drivers of economic benefits and the factors impacting these. To
ensure applicability across Europe, health care settings were analysed for the UK,
France, Germany, Italy, Spain and Poland. Experts were consulted to validate the
model structure and assumptions.RESULTS:A budget impact framework was used
and the model was developed primarily for acute conditions. The model considers
six patient groups which may initiate the switched-to-OTC drug: those on the Rx
drug, other Rx drugs, OTC-treated, untreated, and undiagnosed (OTC-treated and
untreated). From the budget holder perspective, the model includes savings due to
avoided: Rx drug acquisition, doctor’s visits to obtain a prescription and emergency
room visits or hospitalisations due to easier access to an effective or safer therapy.
The policy-maker perspective also includes employers’ benefits, such as less time-
off work to obtain a prescription and less absenteeism & presenteeism due to easier
access to therapies that improve employee productivity. The algorithm to estimate
cost consequences of potential adverse events due to lack of doctor’s supervision
was developed. The model has a 5-year time horizon with a function to conduct an
analysis for one year which may represent the savings at the forecast peak uptake.
An option to estimate the consequences of the disreimbursement policies was
incorporated. The model is particularly sensitive to uptake rates across different
groups of patients. The model is flexible and easily adaptable to different acute
conditions and countries in Europe. CONCLUSIONS: The economic impact associ-
ated with Rx-to-OTC switches can be credibly estimated in Europe. Preliminary
analyses suggest that such switches are cost-saving.
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A LITERATURE REVIEW OF METHODS USED TO ESTIMATE MEAN PREFERENCE-
BASED UTILITIES FOR COMORBIDITIES USING PUBLISHED SUMMARY
STATISTICS
Ara R, Wailoo AJ
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OBJECTIVES: There is currently no consensus on the appropriate method to esti-
mate utilities for joint health conditions. We reviewed the literature to understand
reasons for differences in conclusions drawn and to identify where further re-
search is required. METHODS: We conducted a systematic literature search to
identify studies that evaluated methods used to estimate mean utilities for comor-
bidities using mean values from cohorts with the corresponding single conditions.
We extracted the preference-based utility measure used, the number and range of
estimated utility values, the baseline used to value utility decrements, the statistics
used to compare estimates, and the conclusions of the authors. RESULTS: Four of
the six studies identified used EQ-5D data, one used SF-6D and one used HUI3. One
presented the multiplicative method, one compared the additive and multiplica-
tive methods, and four compared the additive, multiplicative, and minimum meth-
ods with the results obtained from linear models. The number of mean utility
values estimated ranged from 32 to 760 and the range of actual mean values ranged
from 0.465 to 0.607 for SF-6D, to -0.01 to 1 for HUI3. Systematic errors were observed
in the values estimated using all methods. While the simple linear models pro-
duced the most accurate results these require validation. Of the other three, on
average the multiplicative method estimated the most accurate values across the
full range of actual utilities assessed. CONCLUSIONS: While additional research is
required before a particular method can be advocated, based on the current evi-
dence base we would recommend the multiplicative method is used if data are not
available from cohorts with the comorbidities.
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OBJECTIVES: The Brazilian Extended Consumer Price Index (IPCA) for Pharmaceu-
tical Products (IPCA-Pharmaceuticals) measures changes in the prices of a fixed
basket of medicines purchased by Brazilian households. Monitoring, modeling and
prediction of the index are important because adjustments for inflation must be
made in accordance with the principles of good practice in health economic anal-
yses. In addition, the index has an important weight in the calculation of the
General IPCA, the official index to guide inflation-related policies, and is used to
regulate pharmaceutical products prices. The objectives of this study are: 1) to
model the IPCA-Pharmaceuticals time series during the sample period 2006-2010;
and 2) predict the rate of inflation for the year 2011. METHODS: Two classical
methodologies of time series analysis were employed: Holt-Winters exponential
smoothing and the Box-Jenkins approach. Both methods were compared across
three statistics based on errors measures: mean squared error, mean absolute
percent error, and Theil’s U coefficient. The best fitted model was chosen based on
minimizing the error statistics and was used to forecast the IPCA-pharmaceuticals
in 2011. RESULTS: Monthly IPCA-Pharmaceuticals data was collected from July
2006 to December 2010 (n54) from Brazilian Institute of Geography and Statistics.
The IPCA-Pharmaceuticals percentage change time series was converted to index
number on base July 2006100. The Holt-Winters additive method was adjusted
and compared with a SARIMA (0,1,1)x(1,0,0)12 model estimated through the Box-
Jenkins approach. The between-methods comparison showed a large advantage
for the Box-Jenkins, which minimized the three errors measures. CONCLUSIONS:
The Box-Jenkins method presented better results as compared to the Holt-Winters
method. The final forecasting predicted a 2% inflation rate for pharmaceutical
products by the end of 2011, which is lower than the general inflation target rate
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established by the Brazilian government (2.5-6.5%) and below the observed mean
rate in the last three years (4.4%).
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BAYESIAN INFERENCE IN MIXED TREATMENT COMPARISONS (MTC) WITH
CONTINUOUS OUTCOMES
Osiewalski K, Szmurlo D, Rogoz A
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OBJECTIVES: The aim of this paper is to present a compact and coherent within the
Bayesian inference method of best meta-analysis model selection as well as to
present analytical results in performing Gibbs sampling within the MTC
framework. METHODS: In order to perform Gibbs sampling from the posterior
distribution in the random effects model of MTC we evaluate the formulas for the
conditional distributions for all parameters. We test for the existence of between
study heterogeneity and other parametric restrictions by comparing marginal data
densities of competing models. We show how the prior distribution on the model
space may affect the inference about best model selection. As an empirical exam-
ple we present an analysis of effectiveness of two real (although blinded) drugs and
placebo. RESULTS: We present the marginal posterior distributions of key param-
eters as well as the comparison of a few restricted models. Among 18 studies from
the systematic review dealing with treating the analyzed medical issue with drugs
of interest there exist a significant effect of heterogeneity. The a priori distribution
on the space of models does not affect this final conclusion (Bayes factor varies
from 185 to 190 in favor of the unreduced model). The posterior odds ratio (which
equals around 293.1) points that the treatment with Medicine A brings a stronger
effect than with Medicine B or placebo. CONCLUSIONS: Our results show, that
using pure Bayesian techniques can be widely used within the MTC framework. We
present an easy to operate and coherent inference in performing complex meta-
analyses. We also found confirmed, that Medicine A significantly better increases
the level of observed outcome than other treatments.
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OBJECTIVES: To translate, validate and examine the psychometric properties of
the Urdu version of the Morisky Medication Adherence Scale (MMAS) among pa-
tients with hypertension. METHODS: A systematic procedure of ‘‘forward–back-
ward’’ was used to translate MMAS into Urdu (official language of Pakistan). It was
later validated on a convenience sample of 272 established hypertensive patients
between July and October 2010 visiting outpatient department of cardiac ward at
Bolan Medical College Hospital, Quetta, Pakistan. For test-retest reliability, data
was available for 42 patients. Internal consistency was taken as a measure to test
reliability of the MMAS. Convergent and known group validity was taken into ac-
count to confirm the validity. RESULTS: The mean SD of MMAS score was 6.19
1.81, which was measured by applying the recommended scoring method of
Morisky Scale. Internal consistency was found to be moderate (Cronbach’s a 
0.621). Test–retest reliability value was 0.801 (p  0.001). By applying Spearman’s
rho, positive correlation between the eight- and four item MMAS was found (r 
0.792; p  0.01). A significant relationship between MMAS categories and blood
pressure control (2 20.121; p0.001) was found. The MMAS sensitivity and spec-
ificity, with positive and negative predictive values were 71.54%, 41.48%, 44.74%
and 75.56%, respectively. CONCLUSIONS: The findings of this validation study in-
dicate that the Urdu version of the MMAS is a reliable and valid tool for the mea-
surement of medication adherence in Pakistani health system.
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A COMPARISON OF THE PATIENTSLIKEME QUALITY OF LIFE QUESTIONNAIRE
(PLMQOL) WITH THE RAND SF-36
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OBJECTIVES: PatientsLikeMe developed the 24-item PLMQOL to be a brief, easy-to-
complete online patient-reported assessment of health-related quality of life. The
instrument consists of three domains: physical, social, and mental function. As
part of the validation process, we examined the performance of the PLMQOL com-
pared with the RAND SF-36 in a population of patients with chronic disease.
METHODS: Both the PLMQOL and the RAND SF-36 were administered via internet
to 2042 invited members of PatientsLikeMe, a novel health data-sharing website
allowing patients to monitor multidimensional aspects of health and well-being.
Patients were randomized to questionnaire order and were required to have filled
out at least one PLMQOL in the 30 days prior to the Jun 9, 2011 survey deployment
date in order to be eligible. RESULTS: 1228 patients opened the survey invitation,
and 660 (54% of those who opened the invite; 32% of eligible sample) patients
completed the survey over the 10-day window of availability. No significant differ-
ences were seen between the randomized samples by age, sex, condition, or re-
sponse. Respondents represented approximately 100 chronic conditions; most
commonly reported were multiple sclerosis (n147), fibromyalgia (n112), Parkin-
son’s disease (n43), and amyotrophic lateral sclerosis (n42). The PLMQOL dem-
onstrated high reliability across domains of physical (11 items, 0.940-0.944),
mental (8 items, 0.909-0.917, and social function (5 items, 0.810-0.828). In
addition, the PLMQOL was highly correlated with relevant domains of the RAND
SF-36 as demonstrated by Pearson correlation: RAND physical function and
PLMQOL physical function (r0.838-0.855, p0.001); RAND emotional well-being
and PLMQOL mental function (r0.832-0.852, p0.001); RAND social function and
PLMQOL social function (r0.795-0.823, p0.001). CONCLUSIONS: The PLMQOL is a
reliable and valid instrument for online assessment of health-related quality of life,
demonstrating high correlations with relevant domains of the RAND SF-36. Further
research is required to assess disease-specific psychometric properties and clinical
validity.
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DATA POOLING OF PATIENT-REPORTED OUTCOMES IN CLINICAL TRIALS:
EVALUATION OF STRUCTUAL EQUATION MODELLING FOR ASSESSING
EQUIVALENCE
Nixon M, Burgess AJ
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OBJECTIVES: This analysis describes the development, application and compari-
son of three different equivalence approaches to evaluate equivalence properties
of a patient reported outcome (PRO) questionnaire applied to two treatment groups
for gastroesophageal reflux disease (GERD). The data used in this analysis was
obtained from a medication-monitoring disease registry (iGuard). Patients using
either of the two treatments were randomly invited to complete a measure of
treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication
(TSQM). METHODS: Three statistical applications of Confirmatory Factor Analysis
(CFA) using a special case of Structural Equation Modelling (SEM) were used to
evaluate the equivalence of the TSQM in the two patient populations: 1) equality of
the factor scores (measurement equivalence); 2) equality of the variance-covari-
ance matrix (structural equivalence); 3) equality of the measurement error (reli-
ability equivalence). RESULTS: Each statistical test agreed that equivalence had
been achieved between the two treatment populations for all the three domains of
the TSQM. The effectiveness and global satisfaction domains exhibited the stron-
gest significant results on all three tests. However, while the convenience domain
exhibited strongly significant equivalence for the measurement equivalence, it
only exhibited significant results for the structural and reliability equivalence.
CONCLUSIONS:While all three methods indicated the same overall results, there is
some suggestion of differing sensitivity amongst the tests.
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OBJECTIVES: In economic evaluation patient-reported questionnaires are fre-
quently used for data collection on medical consumption and productivity losses.
The TiC-P is a comprehensive questionnaire focused on establishing costs incurred
within the health care system and costs arising from production losses. The ques-
tionnaire was developed for a broad application of collecting data in patients
treated in mental health care. The aim of this study is to assess the questionnaire’s
feasibility and validity. METHODS: Validation included feasibility, consistency
(test-retest) and reliability of reported data. Data were derived from a number of
patients included in a study evaluating the cost-effectiveness of alternative feed-
back mechanisms during psychotherapy. Consistency of the data was assessed
using Cohen’s kappa coefficients (categorical variables) and intraclass correlation
coefficients (ICC) (measurements on interval level). The following values were at-
tached to the coefficients: modest (0.21-0.40); moderate (0.41-0.60); satisfactory
(0.61-0.80) and almost perfect (0.81-1.00). Reliability was assessed comparing re-
ported data with registered contacts with psychiatrist, psychologist or psychother-
apist. Feasibility was based on response rate, and completeness of report on
medication. RESULTS: Re-test analyses were based on retest questionnaires of 99
respondents. Agreement regarding medical services was as follows: moderate: 3
items; satisfactory: 8 items; almost perfect: 1 item. Categorical items related to
productivity losses included short-term and long-term absence from work and
impediment at work. Agreement on these items was satisfactory. ICC’s were cal-
culated for 7 items presenting the number of contacts with health care providers.
For the remaining items on medical services, ICC’s could not be assessed due to
insufficient variation in the data. Agreement was considered modest on 1 item,
satisfactory on 3 items and almost perfect on 3 items. Reliability of reported and
registered number of contacts was 82%. CONCLUSIONS: These preliminary results
indicated that the TiC-P is a valid instrument for measuring medical consumption
and productivity losses.
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SYSTEMATIC REVIEW OF HEALTH STATE UTILITIES IN SPAIN
García-Pérez L1, Aguiar-Ibáñez R2, Linertová R1, Rivero-Santana A1, Abásolo-Alessón I3
1Fundación Canaria de Investigación y Salud (FUNCIS), Santa Cruz de Tenerife, Spain, 2Amaris,
London, UK, 3Universidad de La Laguna, San Cristóbal de La Laguna, Spain
OBJECTIVES: The objective is to identify published studies reporting utility values
or preferences for health states elicited from the Spanish population with the
long-term purpose of maintaining an updated database of utilities that can be of
help for the research community. METHODS: A systematic review was conducted
to identify studies that elicited utilities by means of questionnaires validated in
Spain (EQ-5D, SF-6D, etc.) or accepted techniques (time trade-off, standard gamble,
etc.), from healthy or non-healthy populations. We initially focused in cancer,
diabetes and heart diseases. An electronic search was developed and run in MED-
LINE, EMBASE, PsycINFO, NHS CRD, Cochrane Central Register of Controlled Trials,
CINAHL and Spanish databases. Original utility sources were identified from clin-
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